Access to nonstandard car t-cell therapy
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial provides access to a CAR T-cell therapy (ide-cel) that was made for you but didn't meet commercial release standards. It's an expanded access program for patients who have no other options and are stable enough to receive the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had a batch of the CAR T-cell therapy (ide-cel) made specifically for you that did not meet quality standards for commercial release.
- Your doctor must have decided that making a new batch is not possible or not medically appropriate for you.
- You must be clinically stable, meaning your condition is not rapidly getting worse.
- You must not have an allergy to the drug or its ingredients.
- You must not have any other medical condition or lab abnormality that would put you at unacceptable risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides access to an experimental CAR-T cell therapy called cilta-cel for people with multiple myeloma who have run out of other good options. It is designed for those who qualify for the standard treatment but need special handling because their cell product is out of specification.
This study tests a new CAR-T cell therapy called Eque-cel for people with multiple myeloma that no longer responds to lenalidomide. It aims to see if this treatment can help control the disease after 1-2 prior therapies.
This trial tests a new treatment called CAR-T cell therapy that uses your own immune cells to fight cancer. It is for people with multiple myeloma or plasma cell leukemia that has come back or not responded to other treatments.
This trial tests a one-time cell therapy called ciltacabtagene autoleucel (a CAR-T treatment) in people who have newly diagnosed multiple myeloma and are not eligible for a stem cell transplant. It aims to see if this treatment is safe and effective as an early therapy.
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.